
Thiem D. Phan
Examiner (ID: 17337, Phone: (571)272-4568 , Office: P/3729 )
| Most Active Art Unit | 3729 |
| Art Unit(s) | 3729 |
| Total Applications | 2355 |
| Issued Applications | 1894 |
| Pending Applications | 46 |
| Abandoned Applications | 456 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20720985
[patent_doc_number] => 20260137684
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-05-21
[patent_title] => ROCK2 Inhibitors And Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 19/443292
[patent_app_country] => US
[patent_app_date] => 2026-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10686
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19443292
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/443292 | ROCK2 Inhibitors And Uses Thereof | Jan 7, 2026 | Pending |
Array
(
[id] => 20509955
[patent_doc_number] => 20260034053
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-02-05
[patent_title] => METHODS FOR DOSE INITIATION OF ARIPIPRAZOLE TREATMENTS
[patent_app_type] => utility
[patent_app_number] => 19/352541
[patent_app_country] => US
[patent_app_date] => 2025-10-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4442
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19352541
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/352541 | METHODS FOR DOSE INITIATION OF ARIPIPRAZOLE TREATMENTS | Oct 7, 2025 | Pending |
Array
(
[id] => 19975892
[patent_doc_number] => 12343348
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-01
[patent_title] => Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
[patent_app_type] => utility
[patent_app_number] => 18/988636
[patent_app_country] => US
[patent_app_date] => 2024-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 30091
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18988636
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/988636 | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome | Dec 18, 2024 | Issued |
Array
(
[id] => 19876868
[patent_doc_number] => 20250109125
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-03
[patent_title] => PROCESS FOR MAKING AN ISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/978995
[patent_app_country] => US
[patent_app_date] => 2024-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11407
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 137
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18978995
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/978995 | Process for making an isoxazoline compound and intermediate thereof | Dec 11, 2024 | Issued |
Array
(
[id] => 19897809
[patent_doc_number] => 12275713
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-04-15
[patent_title] => Method for preparing 5-hydroxymethylfurfural
[patent_app_type] => utility
[patent_app_number] => 18/895254
[patent_app_country] => US
[patent_app_date] => 2024-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 5
[patent_no_of_words] => 0
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 140
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18895254
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/895254 | Method for preparing 5-hydroxymethylfurfural | Sep 23, 2024 | Issued |
Array
(
[id] => 19656931
[patent_doc_number] => 20240423996
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-26
[patent_title] => METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME
[patent_app_type] => utility
[patent_app_number] => 18/824811
[patent_app_country] => US
[patent_app_date] => 2024-09-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34762
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18824811
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/824811 | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome | Sep 3, 2024 | Issued |
Array
(
[id] => 19940219
[patent_doc_number] => 12312341
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-27
[patent_title] => Methods for treating cancer
[patent_app_type] => utility
[patent_app_number] => 18/795384
[patent_app_country] => US
[patent_app_date] => 2024-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 124189
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18795384
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/795384 | Methods for treating cancer | Aug 5, 2024 | Issued |
Array
(
[id] => 19793285
[patent_doc_number] => 12234214
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-25
[patent_title] => Method for continuously synthesizing 5-hydroxymethylfurfural by using micro-channel reactor
[patent_app_type] => utility
[patent_app_number] => 18/778902
[patent_app_country] => US
[patent_app_date] => 2024-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 3140
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 298
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18778902
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/778902 | Method for continuously synthesizing 5-hydroxymethylfurfural by using micro-channel reactor | Jul 18, 2024 | Issued |
Array
(
[id] => 19601042
[patent_doc_number] => 20240391922
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS
[patent_app_type] => utility
[patent_app_number] => 18/775532
[patent_app_country] => US
[patent_app_date] => 2024-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25191
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 5
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18775532
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/775532 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | Jul 16, 2024 | Pending |
Array
(
[id] => 19763156
[patent_doc_number] => 12221429
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-11
[patent_title] => Method for synthesizing 1,3,2-dioxathiolane 2,2-dioxide by in-situ catalytic oxidation
[patent_app_type] => utility
[patent_app_number] => 18/770589
[patent_app_country] => US
[patent_app_date] => 2024-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 4517
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 426
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18770589
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/770589 | Method for synthesizing 1,3,2-dioxathiolane 2,2-dioxide by in-situ catalytic oxidation | Jul 10, 2024 | Issued |
Array
(
[id] => 19510443
[patent_doc_number] => 20240342129
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-17
[patent_title] => METHOD OF TREATMENT
[patent_app_type] => utility
[patent_app_number] => 18/751865
[patent_app_country] => US
[patent_app_date] => 2024-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1355
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18751865
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/751865 | METHOD OF TREATMENT | Jun 23, 2024 | Pending |
Array
(
[id] => 19497623
[patent_doc_number] => 20240336641
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-10
[patent_title] => 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/747540
[patent_app_country] => US
[patent_app_date] => 2024-06-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37450
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 599
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18747540
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/747540 | 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | Jun 18, 2024 | Pending |
Array
(
[id] => 19571811
[patent_doc_number] => 20240376103
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-14
[patent_title] => METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS
[patent_app_type] => utility
[patent_app_number] => 18/742346
[patent_app_country] => US
[patent_app_date] => 2024-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13107
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18742346
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/742346 | METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS | Jun 12, 2024 | Pending |
Array
(
[id] => 20023039
[patent_doc_number] => 20250161261
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-22
[patent_title] => Method for Treating Osteoarthritis Pain by Administering Resiniferatoxin
[patent_app_type] => utility
[patent_app_number] => 18/735041
[patent_app_country] => US
[patent_app_date] => 2024-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2813
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18735041
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/735041 | Method for Treating Osteoarthritis Pain by Administering Resiniferatoxin | Jun 4, 2024 | Pending |
Array
(
[id] => 19876874
[patent_doc_number] => 20250109131
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-03
[patent_title] => PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE
[patent_app_type] => utility
[patent_app_number] => 18/655452
[patent_app_country] => US
[patent_app_date] => 2024-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45819
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18655452
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/655452 | PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE | May 5, 2024 | Pending |
Array
(
[id] => 19955284
[patent_doc_number] => 12325690
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-10
[patent_title] => Compounds for the reducing lipotoxic damage
[patent_app_type] => utility
[patent_app_number] => 18/637793
[patent_app_country] => US
[patent_app_date] => 2024-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 40
[patent_no_of_words] => 4466
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18637793
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/637793 | Compounds for the reducing lipotoxic damage | Apr 16, 2024 | Issued |
Array
(
[id] => 20264062
[patent_doc_number] => 12435037
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-07
[patent_title] => Acetylsalicylic acid derivative and application thereof
[patent_app_type] => utility
[patent_app_number] => 18/635657
[patent_app_country] => US
[patent_app_date] => 2024-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 4196
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18635657
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/635657 | Acetylsalicylic acid derivative and application thereof | Apr 14, 2024 | Issued |
Array
(
[id] => 19402093
[patent_doc_number] => 20240285604
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => TARGETED DEGRADATION OF VAV1
[patent_app_type] => utility
[patent_app_number] => 18/633272
[patent_app_country] => US
[patent_app_date] => 2024-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 92254
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18633272
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/633272 | Targeted degradation of VAV1 | Apr 10, 2024 | Issued |
Array
(
[id] => 19360803
[patent_doc_number] => 20240262837
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => DEUTERATED NUCLEOSIDE COMPOUNDS AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/632254
[patent_app_country] => US
[patent_app_date] => 2024-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4124
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18632254
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/632254 | DEUTERATED NUCLEOSIDE COMPOUNDS AND USE THEREOF | Apr 9, 2024 | Pending |
Array
(
[id] => 19599426
[patent_doc_number] => 20240390306
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => Monohydrate Salt of Denatonium Acetate
[patent_app_type] => utility
[patent_app_number] => 18/631587
[patent_app_country] => US
[patent_app_date] => 2024-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5177
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18631587
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/631587 | Monohydrate Salt of Denatonium Acetate | Apr 9, 2024 | Pending |